Core Viewpoint - Beijing Wandong Medical Technology Co., Ltd. announced the share repurchase plan and provided details on the top ten shareholders and top ten unrestricted shareholders as of August 22, 2025 [1]. Summary by Category Share Repurchase Plan - The company has proposed a share repurchase plan, which was disclosed on August 23, 2025, on the Shanghai Stock Exchange [1]. Shareholder Information - The announcement includes the names, shareholdings, and proportions of the top ten shareholders and top ten unrestricted shareholders as of August 22, 2025. - The top shareholders include: 1. China Bank Co., Ltd. - Hua Bao CSI Medical Index Open-End ETF 2. China Merchants Bank Co., Ltd. - Southern CSI 1000 Open-End ETF - All shares listed are unrestricted circulating shares, and the top ten shareholders and top ten unrestricted shareholders have the same shareholding situation [1].

证券代码：600055 证券简称：万东医疗 公告编号：2025-041 北京万东医疗科技股份有限公司关于 以集中竞价交易方式回购股份的回购报告书 ? 回购股份方式：集中竞价交易方式。 ? 回购股份期限：自董事会审议通过本次回购方案之日起 12 个月内。 ? 相关股东是否存在减持计划：经公司问询，公司董事、高级管理人 员、控股股东、实际控制人在未来 3 个月、未来 6 个月不存在减持计划。 若上述主体后续拟实施股份减持计划的，相关方及公司将严格按照相关规 定及时履行信息披露义务。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 回购股份金额：人民币3,000万元（含）-6,000万元（含）。 ? 回购股份资金来源：公司自有资金。 ? 回购股份用途：用于员工持股计划或股权激励。 ? 回购股份价格：不超过25元/股，该价格不高于董事会通过回购股 份决议日前30个交易日公司股票交易均价的150%。 ? 相关风险提示： 导致本次回购方案无法顺利实施的风险； 及时到位，导致回购方案无法按计划实施的风险； 能存在回购 ...

回购股份期限：自董事会审议通过本次回购方案之日起 12 个月内。 北京万东医疗科技股份有限公司关于 以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 回购股份金额：人民币3,000万元（含）-6,000万元（含）。 回购股份价格：不超过25元/股，该价格不高于董事会通过回购股 份决议日前30个交易日公司股票交易均价的150%。 回购股份方式：集中竞价交易方式。 证券代码：600055 证券简称：万东医疗 公告编号：2025-041 相关股东是否存在减持计划：经公司问询，公司董事、高级管理人 员、控股股东、实际控制人在未来 3 个月、未来 6 个月不存在减持计划。 若上述主体后续拟实施股份减持计划的，相关方及公司将严格按照相关规 定及时履行信息披露义务。 相关风险提示： 1、本次回购可能存在回购期限内公司股票价格持续超出回购价格上限， 导致本次回购方案无法顺利实施的风险； 2、本次回购股份的资金来源于自有资金，存在回购股份所需资金未能 及时到位，导致回购方案无法按计划实施 ...

证券代码：600055 证券简称：万东医疗 编号：临 2025-042 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：自有资金 0.8 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用自有资金 0.1 亿元， 子公司使用自 有资金 0.7 亿元。 （三）资金来源 ...

特此公告。 北京万东医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开第十届董事会第十次会议，审议通过了《关于以集中竞价交易方 式回购公司股份方案的议案》。具体内容详见公司于 2025 年 8 月 23 日在上 海证券交易所网站披露的《万东医疗关于以集中竞价交易方式回购股份方 案的公告》（公告编号：2025-038）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指 引第7号—回购股份》等相关规定，现将董事会公告回购股份决议的前一个 交易日（即2025年8月22日）登记在册的前十大股东和前十大无限售条件股 东的名称、持股数量及比例情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例 | | --- | --- | --- | --- | | | | | （%） | | 1 | 美的集团股份有限公司 | 319,579,981 | 45.46 | | 2 | 江苏鱼跃科技发展有限公司 | 18,031,825 | 2.56 | | 3 | 中国银行股份有限公司－华宝中证医疗 交易型开放式指数证券投资基金 | 12,687,111 | 1.80 ...

Core Insights - The company reported a revenue of 843 million yuan, representing a year-on-year increase of 20.46% [1] - The net profit attributable to shareholders was 51.3 million yuan, showing a year-on-year decline of 39.46% [1] - Research and development investment increased by 59.16%, with an R&D intensity of 15% [1] Business Strategy - The company is leveraging the "Healthy China 2030" strategy, focusing on breakthroughs in high-end medical imaging equipment technology and global market expansion [1] - In response to global supply chain adjustments and structural upgrades in the industry, the company is enhancing its R&D system, deepening market layout, and optimizing industrial collaboration [1] Technological Advancements - The company has made significant technological progress, with one-third of its workforce dedicated to R&D, focusing on high-end CT and self-developed core components [1] - The world's first helium-free MR has achieved mass production, eliminating the "bottleneck" risk associated with helium supply [1] - The quantum DSA, utilizing a self-controlled rare earth detector, is leading the way in low-dose angiography [1] - As of June 2025, the company has been granted 243 authorized intellectual property rights, which are widely applied in its main business [1]

Core Points - WanDong Medical's stock price increased by 2.67% to 18.05 yuan as of August 22, 2025, with a market capitalization of 12.69 billion yuan [1] - The company reported a decrease in the number of shareholders by 11.69% to 26,800 as of June 30, 2025, with an increase in average shareholding [2][5] - The company's mid-year report for 2025 showed a 20.46% increase in revenue to 843.33 million yuan, but a significant decline in net profit by 39.46% to 51.30 million yuan [3][5] Shareholder Changes - As of June 30, 2025, the number of shareholders decreased by 3,552, representing an 11.69% reduction [2][5] - The average number of shares held per shareholder increased from 23,100 to 26,200, with an average holding value of 452,800 yuan [2] Performance Highlights - For the first half of 2025, the company reported a total revenue of 843.33 million yuan, a year-on-year increase of 20.46% [3] - The net profit attributable to shareholders decreased by 39.46% to 51.30 million yuan, while the net profit excluding non-recurring items fell by 56.07% to 35.63 million yuan [3] - The second quarter of 2025 saw a revenue of 470 million yuan, up 20.04% year-on-year, but net profit dropped by 68.44% to 16.25 million yuan [3] Corporate Announcements - The board approved the 2025 semi-annual report and a stock option incentive plan, granting 1.2 million stock options to 14 individuals at an exercise price of 15.05 yuan per share [4][6] - The company plans to repurchase shares worth between 30 million and 60 million yuan, with a maximum repurchase price of 25 yuan per share [6]

证券代码：600055 证券简称：万东医疗 公告编号：2025-038 北京万东医疗科技股份有限公司 关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 回购股份金额：人民币 3,000 万元（含）-6,000 万元（含）。 ? 回购股份资金来源：公司自有资金。 ? 回购股份价格：不超过25元/股，该价格不高于董事会通过回购股 份决议日前30个交易日公司股票交易均价的150%。 ? 回购股份方式：集中竞价交易方式。 ? 回购股份期限：自董事会审议通过本次回购方案之日起 12 个月内。 ? 相关股东是否存在减持计划：经公司问询，公司董事、高级管理人 员、控股股东、实际控制人在未来3个月、未来6个月不存在减持计划。若 上述主体后续拟实施股份减持计划的，相关方及公司将严格按照相关规定 及时履行信息披露义务。 ? 相关风险提示： 导致本次回购方案无法顺利实施的风险； 及时到位，导致回购方案无法按计划实施的风险； 能存在回购方案无法顺利实施或者根据规则变更或终止本次回购方案的 ...

Group 1 - The latest stock price of Wandong Medical is 18.05 yuan, up 0.84% from the previous trading day, with an opening price of 17.89 yuan, a high of 18.14 yuan, and a low of 17.86 yuan, with a trading volume of 98,145 hands and a transaction amount of 177 million yuan [1] - Wandong Medical focuses on the research, production, and sales of medical imaging equipment, including CT, MRI, and DR devices, and has made significant technological advancements, including the clinical validation of the world's first helium-free superconducting MRI and the application of multiple AI technologies [1] - The latest semi-annual report for 2025 shows that the company achieved an operating income of 843 million yuan in the first half of the year, a year-on-year increase of 20.46%, but the net profit attributable to shareholders decreased by 39.46% to 51.3 million yuan [1] - In the second quarter, the operating income was 470 million yuan, a year-on-year increase of 20.0%, while the net profit attributable to shareholders dropped by 68.4% to 16.25 million yuan [1] - The company's R&D investment increased by 59.16% year-on-year, with an R&D intensity of 15% [1] Group 2 - The net inflow of main funds for Wandong Medical today was 11.07 million yuan, with a cumulative net inflow of 8.30 million yuan over the past five days [2]

| 股票简称：万东医疗 | | 证券代码：600055 | | --- | --- | --- | | 华泰联合证券有限责任公司 | | | | 关于 | | | | 北京万东医疗科技股份有限公司 | | | | 向2025年股票期权激励计划 | | | | 激励对象授予预留股票期权 | | | | 之 | | | | 独立财务顾问报告 | | | | 二零二五年八月 | | | | （二）关于本次授予事项与股东大会审议通过的激励计划是否存在差异的说明 | | ... 8 | | 一、释义 | | | | 本报告中，除非文义载明，下列简称具有如下含义： | | | | 万东医疗、公司 | | 指 北京万东医疗科技股份有限公司 | | 北京万东医疗科技股份有限公司 | | 2025 年股票期权激励计划（草 | | 本激励计划、本计划 | | 指 | | 案） | | | | | | 公司授予激励对象在未来一定期限内以预先确定的价格和条件购 | | 股票期权、期权 | | 指 | | 买公司一定数量股票的权利 | | | | | | 按照本激励计划规定，获得股票期权的公司（含子公司）董事、 | | 激励对象 | ...